ARTICLE | Company News
University of Montreal, AmorChem deal
August 18, 2014 7:00 AM UTC
The University of Montreal granted VC fund AmorChem exclusive, worldwide rights to a program targeting CD36 (GPIV) to treat atherosclerosis. AmorChem, which invested an undisclosed amount in the prog...